Document Detail


Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.
MedLine Citation:
PMID:  17287847     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our objective was to review all published trials of coenzyme Q10 for hypertension, assess overall efficacy and consistency of therapeutic action and side effect incidence. Meta-analysis was performed in 12 clinical trials (362 patients) comprising three randomized controlled trials, one crossover study and eight open label studies. In the randomized controlled trials (n=120), systolic blood pressure in the treatment group was 167.7 (95% confidence interval, CI: 163.7-171.1) mm Hg before, and 151.1 (147.1-155.1) mm Hg after treatment, a decrease of 16.6 (12.6-20.6, P<0.001) mm Hg, with no significant change in the placebo group. Diastolic blood pressure in the treatment group was 103 (101-105) mm Hg before, and 94.8 (92.8-96.8) mm Hg after treatment, a decrease of 8.2 (6.2-10.2, P<0.001) mm Hg, with no significant change in the placebo group. In the crossover study (n=18), systolic blood pressure decreased by 11 mm Hg and diastolic blood pressure by 8 mm Hg (P<0.001) with no significant change with placebo. In the open label studies (n=214), mean systolic blood pressure was 162 (158.4-165.7) mm Hg before, and 148.6 (145-152.2) mm Hg after treatment, a decrease of 13.5 (9.8-17.1, P<0.001) mm Hg. Mean diastolic blood pressure was 97.1 (95.2-99.1) mm Hg before, and 86.8 (84.9-88.8) mm Hg after treatment, a decrease of 10.3 (8.4-12.3, P<0.001) mm Hg. We conclude that coenzyme Q10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects.
Authors:
F L Rosenfeldt; S J Haas; H Krum; A Hadj; K Ng; J-Y Leong; G F Watts
Related Documents :
8752037 - Value of toe pulse waves in addition to systolic pressures in the assessment of the sev...
7484737 - Use of a tantalum-178 generator and a multiwire gamma camera to study the effect of the...
20539177 - Potassium in hemorrhagic shock: a potential marker of tissue hypoxia.
15871757 - Reducing ventilation frequency during cardiopulmonary resuscitation in a porcine model ...
23028797 - Ocean acidification accelerates reef bioerosion.
2874067 - Management of pregnancy-induced hypertension with pindolol--comparative study with meth...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2007-02-08
Journal Detail:
Title:  Journal of human hypertension     Volume:  21     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-15     Completed Date:  2007-07-31     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  297-306     Citation Subset:  IM    
Affiliation:
Cardiac Surgical Research Unit, Alfred Hospital, Melbourne, Australia. f.rosenfeldt@alfred.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Pressure / drug effects*
Clinical Trials as Topic*
Coenzymes / adverse effects,  pharmacology,  therapeutic use
Cross-Over Studies
Databases, Factual
Humans
Hypertension / drug therapy*,  physiopathology
Randomized Controlled Trials as Topic
Research Design
Treatment Outcome
Ubiquinone / adverse effects,  analogs & derivatives*,  pharmacology,  therapeutic use
Vitamins / adverse effects,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Coenzymes; 0/Vitamins; 1339-63-5/Ubiquinone; 303-98-0/coenzyme Q10

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Shear stress increases Cu/Zn SOD activity and mRNA expression in human endothelial progenitor cells.
Next Document:  Use of beta-blockers for uncomplicated hypertension in the elderly: a cause for concern.